This is your clinical reference guide to the Guardant Health precision oncology test portfolio available through Southern CDC.
Each test listed below includes an overview of its purpose. For comprehensive technical specifications, each section links directly to the relevant documentation on the Guardant Health AMEA website.
Whether you are ordering for the first time or reviewing options for a specific patient, this hub is designed to support confident, informed clinical decision-making.
Guardant 360 Liquid (Expanded Panel)
Expanded Liquid Testing With Genomic and Epigenomic Insights
Guardant360 Liquid is the first and only liquid biopsy to deliver genomic and epigenomic insights for a more complete view of cancer. By analyzing cell-free DNA, Guardant360 Liquid helps healthcare providers detect actionable genomic and epigenomic alterations to guide personalized treatment and monitor tumor evolution.
Guardant 360 CDx (74-Gene Panel)
A Fast CGP Panel with Guideline-Recommended Actionable Biomarkers
Our Guardant360 CDx test is our FDA-approved liquid biopsy that provides results in 7 days upon sample receipt in the laboratory to inform treatment decisions.
Guardant 360 (Tissue)
Unlock Maximum Insights From Minimal Tissue With Advanced Multiomics.
Guardant360 Tissue is a multiomic test for patients with advanced solid tumors, providing comprehensive genomic, transcriptomic, and epigenomic insights using minimal tissue—requiring 92% less surface area and 40% fewer slides than the industry standard.
Guardant 360 (Reveal)
Minimal Residual Disease Detection and Therapy Response Monitoring
Guardant Reveal is a simple blood test that utilizes circulating tumor DNA (ctDNA) to detect cancer at the molecular level, offering a more precise, ctDNA-guided approach to cancer monitoring. Guardant Reveal is available for molecular residual disease (MRD) detection and recurrence monitoring in early-stage colorectal, breast, and lung cancers and for therapy response monitoring in advanced cancer.